Hot Investor Mandate: Corporate VC Provides Services for Equity

10 Oct

The corporate VC is the strategic advisory and equity investment arm of a holding company and its CRO affiliate. The firm invests a portion of the normal cost of IND-enabling animal toxicology and pharmacology study services conducted by the CRO in companies and receives equity positions in exchange. The firm seeks to invest in companies located in the U.S. only.

The corporate VC is currently looking for companies developing therapeutics and considers both small molecules and biologics. The firm is open to most therapeutic indications, but generally is not interested in programs in the CNS or respiratory disease spaces. The firm is particularly interested in companies developing new therapies to treat ocular diseases where its CRO affiliate has highly specialized technology and significant expertise.

The firm does not lead investment rounds and acts only as a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Asia Introduces New Panel Content and All-Day Entrepreneur Pitch Track

3 Oct

By Lucy Parkinson, VP of Investor Research, LSN

As we take RESI from city to city across the world, LSN’s content team has tailored RESI’s panels and workshops to current trends in each of the locales that have played host to RESI.  Both Shanghai and Taipei have regional expertise that have provided new panel topics.  At RESI Shanghai, those new topics include Next Generation China CRO Capability, Different Partnership Models with China, and the return of the AI in Healthcare panel.

At RESI Taipei, we will draw on the local expertise for our new panel on Smart Hospital & Homecare, plus the return of two sessions that tap into Taipei’s local expertise – Investing in Genomics and Investing in Cell & Gene Therapy.

Additionally, as a response to the Asia style of doing business, both RESI Shanghai and RESI Taipei will feature an all-day Entrepreneur Pitch Challenge where investors will provide feedback and advice to successful applicants from the RESI Innovation Challenge.

If you’d like to take part in RESI as an investor, please get in touch with us at research@lifesciencenation.com – we are interested in hearing from potential panel speakers and pitch judges.

500+ Early Stage Investors Converge on RESI San Francisco – Jan.14, 2020

3 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

RESI San Francisco has become the key venue to meet early stage investors and companies during the annual January healthcare conference week.  Millions upon millions of dollars have been invested in early stage companies following a connection at RESI SF.  In January of this year, RESI SF’s partnering system was booked to capacity, with early stage companies and investors – 1200 attendees in total – connecting all day both in scheduled and ad hoc meetings.

LSN will be launching the 2020 RESI calendar with RESI SF on January 14th at the Marine’s Memorial Club and Hotel.  For the last two years, RESI SF registration has closed early due to selling to capacity – we recommend registering early to reserve your spot for this event!

%d bloggers like this: